8-K: Valion Bio Reports Q1 2026 Results, Advances Entolimod Platform

Valion Bio (formerly Tivic Health) reported first quarter 2026 financial results, highlighting progress in its Entolimod platform, government engagement, and integration of Velocity Bioworks.

Summary

• Valion Bio, formerly Tivic Health Systems, Inc., reported its first quarter 2026 financial results ending March 31, 2026.
• The company completed its corporate transformation, changing its name to Valion Bio, Inc. and its Nasdaq ticker to VBIO.
• Key developments include advancing the Entolimod platform for Acute Radiation Syndrome (ARS) and engaging with U.S. government agencies like BARDA and NIAID for potential procurement and stockpiling.
• Integration of Velocity Bioworks, a CDMO subsidiary acquired in December 2025, is progressing, supporting internal manufacturing and third-party business development.
• The company is also advancing Entolasta, a next-generation TLR5 agonist for oncology supportive care, longevity, and immunosenescence.
• Operating expenses for Q1 2026 were $5.6 million, up from $1.4 million in Q1 2025, primarily due to the inclusion of Velocity Bioworks and corporate rebranding costs.
• Net loss for Q1 2026 was $6.2 million ($2.23 per share), compared to a net loss of $1.5 million ($2.52 per share) in Q1 2025.
• Cash and cash equivalents stood at $7.2 million as of March 31, 2026, down from $12.6 million at December 31, 2025, with the company evaluating capital alternatives.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting significant operational progress and strategic realignment, but also increased expenses and a widening net loss with a notable decrease in cash reserves.

Positives

• Completed corporate transformation and rebranding to Valion Bio, Inc. (VBIO) to focus on immunotherapeutics.
• Advanced engagement with U.S. government agencies (BARDA, NIAID, Department of War) for Entolimod as a medical countermeasure for ARS.
• Continued integration of Velocity Bioworks, enhancing manufacturing capabilities and creating a potential new revenue stream.
• Reinforced regulatory pathway for Entolimod with FDA's Animal Rule, supported by Fast Track and Orphan Drug designations.
• Advancing Entolasta, a next-generation TLR5 agonist with potential applications in oncology supportive care, longevity, and immunosenescence.
• Maintained domestic biologics manufacturing footprint through Velocity Bioworks, addressing internal needs and the Phase I/II CDMO market.

Negatives

• Operating expenses increased significantly to $5.6 million in Q1 2026 from $1.4 million in Q1 2025, driven by the acquisition of Velocity Bioworks and rebranding costs.
• Net loss widened to $6.2 million in Q1 2026 from $1.5 million in Q1 2025.
• Cash and cash equivalents decreased to $7.2 million as of March 31, 2026, from $12.6 million as of December 31, 2025.
• Net loss per share was $2.23 in Q1 2026, compared to $2.52 in Q1 2025, though the weighted-average shares outstanding increased significantly.

Risks

• Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially.
• Potential for actual results, performance, or achievements to differ materially and adversely from those expressed in forward-looking statements.
• Risks associated with the company's interactions with and guidance from the FDA and other regulatory authorities.
• Continued interest and potential procurement/stockpiling by U.S. government agencies like BARDA and NIAID for Entolimod.
• Ability to achieve expected benefits from the acquisition of Velocity Bioworks within expected timeframes or at all.
• Failure to obtain FDA or similar clearances or approvals, and noncompliance with FDA or similar regulations, including related to the Animal Rule.
• The company's need for, and ability to secure, additional working capital to support continued execution against milestones.

Future Outlook

The company believes it enters the balance of 2026 with sharper focus, deeper engagement, and broader optionality. It is evaluating capital alternatives to support continued execution against pipeline, regulatory, and manufacturing milestones.

Management Comments

• The transition to Valion Bio is more than a change of name and ticker. It reflects the institutional identity we have built - a clinical-stage immunotherapeutics company anchored by a differentiated TLR5 platform, an in-house biologics manufacturing capability through Velocity Bioworks, and increasing visibility within the federal agencies responsible for national medical countermeasure preparedness.
• Each of those pillars advanced through the first quarter, and we believe the company enters the balance of 2026 with sharper focus, deeper engagement, and broader optionality than at any point in our history.
• Beyond Entolimod's role in radiation defense, the most significant commercial opportunity in front of us is oncology supportive care. Neutropenia and related conditions affect a meaningful proportion of patients undergoing chemotherapy and radiation therapy, and the mechanistic profile of Entolimod - together with the broader applicability of our second-generation molecule, Entolasta - positions us to address that market with a differentiated entry.
• Velocity Bioworks accelerates our path on both fronts: it compresses our internal development timelines, structurally lowers our manufacturing cost base, and creates a stand-alone CDMO revenue stream serving the broader biotech industry.
• The first quarter was a quarter of execution, and we are building.

Industry Context

StockSavvy.ai notes that Valion Bio's strategic shift towards immunotherapeutics and its focus on medical countermeasures for ARS align with increasing government interest in biodefense and pandemic preparedness. The integration of a CDMO subsidiary like Velocity Bioworks is a common strategy for clinical-stage biotechs to control manufacturing costs and timelines, while also diversifying revenue.

Stakeholder Impact

• Shareholders: The rebranding and strategic focus on immunotherapeutics may offer long-term growth potential, but the increased expenses, net loss, and reduced cash position present near-term financial considerations.
• Employees: Continued integration of Velocity Bioworks and advancement of pipeline programs suggest ongoing operational activity and potential for growth within the company.
• Government Agencies (BARDA, NIAID): Continued engagement on Entolimod for ARS could lead to significant partnerships and funding opportunities.
• Customers (CDMO): Velocity Bioworks' focus on Phase I/II biologics manufacturing addresses a market need, potentially benefiting biotech clients seeking domestic manufacturing.

Next Steps

• Continue advancement of the Entolimod platform towards potential approval under the FDA's Animal Rule for medical countermeasures and oncology supportive care.
• Further integration of Velocity Bioworks, supporting internal pipeline manufacturing and pursuing third-party CDMO business development.
• Advance Entolasta, the next-generation TLR5 agonist, for broader therapeutic applications.
• Engage with U.S. government agencies for potential procurement and stockpiling of Entolimod.
• Evaluate capital alternatives to fund future milestones.

Key Dates

Recommendation

The company has made significant strategic progress with its rebranding and integration of manufacturing capabilities, alongside advancing its lead drug candidate. However, the increased operating expenses, widening net loss, and reduced cash position warrant a cautious 'hold' until further clarity on capital raising and the commercial viability of its pipeline is established.

Keywords

Valion Bio, Tivic Health, Entolimod, Velocity Bioworks, Immunotherapeutics, Acute Radiation Syndrome, CDMO, SEC Filing